ArticleCancer medicine2023

Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer.

Longrong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.